With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway
Executive Summary
Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.
You may also be interested in...
J&J Lays Out ‘Responsibly Cautious’ Growth Outlook
The company's 2023 revenue guidance calls for 4.5%-5.5% growth, taking into account ongoing macroeconomic uncertainty and inflationary pressures.
Pfizer Leads An Unusual Year For The Scrip 100
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.